Novo Nordisk A/S $NVO Holdings Lifted by Parkwood LLC

Key Points

• Parkwood LLC increased its stake in Novo Nordisk A/S by 76.8%, owning a total of 462,571 shares, making it the company's 3rd largest position.
• Shares of Novo Nordisk A/S currently trade at $55.15, with a market capitalization of $246.23 billion and a P/E ratio of 15.15.
• Novo Nordisk A/S recently reported $0.97 EPS for the quarter, surpassing analysts' estimates and maintaining a 35.60% net margin.

Parkwood LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 76.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 462,571 shares of the company's stock after buying an additional 200,976 shares during the period. Novo Nordisk A/S accounts for approximately 2.9% of Parkwood LLC's investment portfolio, making the stock its 3rd largest position. Parkwood LLC's holdings in Novo Nordisk A/S were worth $32,121,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in NVO. Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $27,000. Park Square Financial Group LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $29,000. Stone House Investment Management LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $30,000. Finally, Disciplina Capital Management LLC boosted its holdings in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after acquiring an additional 297 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NVO. UBS Group cut Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday, August 5th. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 20th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 31st. Finally, TD Cowen reduced their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Stock Down 1.8%

Shares of NVO traded down $0.99 during midday trading on Friday, reaching $55.15. The stock had a trading volume of 15,486,058 shares, compared to its average volume of 14,238,722. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $138.22. The company's fifty day simple moving average is $59.46 and its two-hundred day simple moving average is $67.40. The company has a market cap of $246.23 billion, a price-to-earnings ratio of 15.15, a PEG ratio of 2.10 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.